11th Jun 2015 11:13
LONDON (Alliance News) - GW Pharmaceuticals PLC said Thursday it has begun the second of two phase 3 clinical trials of Epidiolex for the treatment of rare childhood epilepsy Lennox-Gastaut syndrome.
The company got an orphan drug designation for Epidiolex for the treatment of Lennox-Gastaut syndrome during 2014.
It expects top-line data from this trial to be available in the first quarter of 2016.
"With the commencement of this trial, GW's pivotal program of four Phase 3 trials for Epidiolex in Dravet syndrome and Lennox-Gastaut syndrome is now fully underway," said Chief Executive Officer Justin Gover in a statement.
Shares in GW Pharmaceuticals are trading up 1.5% at 660.50 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L